These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. COVID-19-associated mucormycosis: Evidence-based critical review of an emerging infection burden during the pandemic's second wave in India. Aranjani JM; Manuel A; Abdul Razack HI; Mathew ST PLoS Negl Trop Dis; 2021 Nov; 15(11):e0009921. PubMed ID: 34793455 [TBL] [Abstract][Full Text] [Related]
25. Short intravenous amphotericin B followed by oral posaconazole using a simple, stratified treatment approach for diabetes or COVID-19-associated rhino-orbito-cerebral mucormycosis: author's response. Mukaka M; Manesh A; Varghese GM Clin Microbiol Infect; 2023 Nov; 29(11):1463-1464. PubMed ID: 37516382 [No Abstract] [Full Text] [Related]
26. Rhino-orbital mucormycosis: Our experiences with clinical features and management in a tertiary care center. Singh SP; Rana J; Singh VK; Singh R; Sachan R; Singh S; Jain S Rom J Ophthalmol; 2021; 65(4):339-353. PubMed ID: 35087975 [No Abstract] [Full Text] [Related]
27. The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis. Ahmadikia K; Hashemi SJ; Khodavaisy S; Getso MI; Alijani N; Badali H; Mirhendi H; Salehi M; Tabari A; Mohammadi Ardehali M; Kord M; Roilides E; Rezaie S Mycoses; 2021 Aug; 64(8):798-808. PubMed ID: 33590551 [TBL] [Abstract][Full Text] [Related]
28. Rhino-orbital-cerebral mucormycosis: fungal epidemic in a viral pandemic. Chouhan M; Solanki B; Shakrawal N J Laryngol Otol; 2021 Nov; 135(11):981-986. PubMed ID: 34470691 [TBL] [Abstract][Full Text] [Related]
30. Outcomes and factors affecting them in patients with rhino-orbito-cerebral mucormycosis. Kashkouli MB; Abdolalizadeh P; Oghazian M; Hadi Y; Karimi N; Ghazizadeh M Br J Ophthalmol; 2019 Oct; 103(10):1460-1465. PubMed ID: 30514712 [TBL] [Abstract][Full Text] [Related]
31. Risk factors and outcomes of COVID associated mucormycosis in kidney transplant recipients. Bansal SB; Rana A; Babras M; Yadav D; Jha P; Jain M; Sethi SK Transpl Infect Dis; 2022 Apr; 24(2):e13777. PubMed ID: 34932870 [TBL] [Abstract][Full Text] [Related]
32. Rhino-orbito-cerebral mucormycosis: five cases. Toumi A; Larbi Ammari F; Loussaief C; Hadhri R; Ben Brahim H; Harrathi K; Ben Romdhane F; Koubaa J; Chakroun M Med Mal Infect; 2012 Dec; 42(12):591-8. PubMed ID: 23116703 [TBL] [Abstract][Full Text] [Related]
33. An interesting report of COVID-19 associated mucormycosis (CAM) cases by two different species of Mucorales. Kaur H; Kanaujia R; Nayak G; Ramavat AS; Patro S; Ghosh A; Chakrabarti A; Rudramurthy SM Indian J Med Microbiol; 2024; 50():100656. PubMed ID: 38925278 [TBL] [Abstract][Full Text] [Related]
34. Diabetes, COVID 19 and mucormycosis: Clinical spectrum and outcome in a tertiary care medical center in Western India. Mishra Y; Prashar M; Sharma D; Akash ; Kumar VP; Tilak TVSVGK Diabetes Metab Syndr; 2021; 15(4):102196. PubMed ID: 34246939 [TBL] [Abstract][Full Text] [Related]
35. Retrobulbar Injection of Amphotericin B in Patients With COVID-19 Associated Orbital Mucormycosis: A Systematic Review. Sharifi A; Akbari Z; Shafie'ei M; Nasiri N; Sharifi M; Shafiei M; Zand A Ophthalmic Plast Reconstr Surg; 2022 Sep-Oct 01; 38(5):425-432. PubMed ID: 35943425 [TBL] [Abstract][Full Text] [Related]
36. Epidemiology, clinical presentation and management of COVID-19 associated mucormycosis: A single centre experience from Pune, Western India. Dravid A; Kashiva R; Khan Z; Bande B; Memon D; Kodre A; Mane M; Pawar V; Patil D; Kalyani S; Raut P; Bapte M; Saldanha C; Chandak D; Patil T; Reddy S; Bhayani K; Suresh L; Dillibabu V; Srivastava S; Khandelwal S; More S; Shakeel A; Pawar M; Nande P; Harshe A; Kadam S; Hallikar S; Kamal N; Andrabi D; Bodhale S; Raut A; Chandrashekhar S; Raman C; Mahajan U; Joshi G; Mane D Mycoses; 2022 May; 65(5):526-540. PubMed ID: 35212032 [TBL] [Abstract][Full Text] [Related]
37. Risk Factors of COVID-19 Associated Mucormycosis (CAM) in Iranian Patients: A Single-Center Retrospective Study. Tavakolpour S; Irani S; Yekaninejad MS; Alimardi M; Hasibi M; Abdollahi H; Kazemi MA; Lotfi M; Shahbazian H; Nazemian Yazdi NA; Samimiardestani S; Firouzifar M; Farahbakhsh F; Mirzaee Goodarzi M; Feiz F; Salehinia F Mycopathologia; 2022 Dec; 187(5-6):469-479. PubMed ID: 36202942 [TBL] [Abstract][Full Text] [Related]
38. COVID-19 associated mucormycosis: A Descriptive Multisite Study from India. Gupta R; Kesavadev J; Krishnan G; Agarwal S; Saboo B; Shah M; Mittal A; Durani S; Luthra A; Singhal A; Rasheed M; Rao GVS; Tripathi V; Jha A; Ghosh A; Mohan V; Singh AK; Phatak S; Panicker J; Bhadada SK; Joshi S; Pal R; Mithal A; Vikram N; Misra A Diabetes Metab Syndr; 2021; 15(6):102322. PubMed ID: 34717135 [TBL] [Abstract][Full Text] [Related]
39. Amphotericin-B-Induced Chronic Kidney Disease in a Post-COVID-19 Patient with Widespread Rhinocerebral Mucormycosis and Pneumonia: A Case Report. Johri N; Choudhary A; Rawat U; Vengat M Curr Drug Saf; 2024; 19(4):474-477. PubMed ID: 37537934 [TBL] [Abstract][Full Text] [Related]
40. Clinical Characteristics, Prognosis Factors and Metagenomic Next-Generation Sequencing Diagnosis of Mucormycosis in patients With Hematologic Diseases. Wang J; Liu L; Li J; Feng X; Yi H; Jiang E; Zheng Y; Zhang F; Zhu X; Mi Y; Han M; Wang J; Feng S Mycopathologia; 2024 Aug; 189(4):71. PubMed ID: 39088077 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]